Form 4: Tarsus Pharmaceuticals Director Transfers Shares to Family Trust

Sentiment:

SEC Form 4 Filing


Scott W. Morrison, a director at Tarsus Pharmaceuticals, transferred 6,016 shares of common stock to the Morrison-Minton Family 2004 Trust on September 30, 2024.

Summary

  • On September 30, 2024, Scott W. Morrison, a director of Tarsus Pharmaceuticals, transferred 6,016 shares of common stock to the Morrison-Minton Family 2004 Trust.
  • The transfer was executed at a price of $0 per share.
  • Following the transaction, Morrison directly owns 0 shares and indirectly owns 6,016 shares through the trust.
  • Morrison serves as the trustee, and he and his spouse are the sole beneficiaries of the trust.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing regarding a share transfer. It doesn't convey any positive or negative sentiment about the company's performance or future prospects.

Industry Context

This is a routine disclosure of insider transactions and doesn't necessarily indicate a change in the company's prospects or management's confidence.

Related Party Transactions

  • The transfer of shares to the Morrison-Minton Family 2004 Trust is a related party transaction.

Stakeholder Impact

  • The transfer of shares to a family trust is unlikely to have a significant impact on stakeholders.

Key Dates

DateDescription
09/30/2024Date of the share transfer to the Morrison-Minton Family 2004 Trust
10/02/2024Date of signature for the Form 4 filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.